Literature DB >> 21871155

Simultaneous detection of ten psychedelic phenethylamines in urine by gas chromatography-mass spectrometry.

Sarah Kerrigan1, Stephanie Banuelos, Laura Perrella, Brittany Hardy.   

Abstract

Psychedelic phenethylamines are an emerging class of designer drugs capable of producing a complex array of sought after adrenergic and hallucinogenic effects. Toxicological detection poses a number of challenges to laboratories. The purpose of this study was to develop a procedure for the detection of psychedelic amphetamines using techniques that are widely accepted in forensic toxicology laboratories. In all, 10 target analytes were selected: 2,5-dimethoxy-4-bromophenethylamine (2C-B), 2,5-dimethoxyphenethylamine (2C-H), 2,5-dimethoxy-4iodophenethylamine (2C-I), 2,5-dimethoxy-4ethylthiophenethylamine (2C-T-2), 2,5-dimethoxy-4-(n)propylthiophenethylamine (2C-T-7), 4-methylthioamphetamine (4-MTA), 2,5-dimethoxy-4-bromoamphetamine (DOB), 2,5-dimethoxy-4-ethylamphetamine (DOET), 2,5-dimethoxy4-iodoamphetamine (DOI), and 2,5-dimethoxy-4methylamphetamine (DOM). Target drugs in urine were analyzed by gas chromatography in selected ion monitoring mode after mixed-mode solid-phase extraction. Limits of detection for all analytes were 2-10 ng/mL, and limits of quantitation were 10 ng/mL or less. Precision evaluated at 50 and 500 ng/mL yielded CVs of 0.4-7.9% and accuracy in the range 91-116%. Calibration curves were linear to 1500 ng/mL using mescaline-d₉ as the internal standard. No carryover was evident at 5000 ng/mL (the highest concentration tested) and no interferences were observed from the presence of other structurally related compounds or endogenous bases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871155     DOI: 10.1093/anatox/35.7.459

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  1 in total

1.  Analysis of synthetic cannabinoids using high-resolution mass spectrometry and mass defect filtering: implications for nontargeted screening of designer drugs.

Authors:  Megan Grabenauer; Wojciech L Krol; Jenny L Wiley; Brian F Thomas
Journal:  Anal Chem       Date:  2012-06-20       Impact factor: 6.986

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.